Heart failure is a disease that affects approximately 26 million people worldwide [1]. This condition is responsible for 17.5 million deaths annually, representing 31% of global mortality [2]; it constitutes a major public health problem worldwide [3].

Heart failure is divided into three main types: heart failure with reduced ejection fraction (HFrEF), heart failure with moderate ejection fraction (HFmEF), and heart failure with preserved ejection fraction (HFpEF). In HFrEF, the left ventricular ejection fraction is less than 40%, in HFmEF it is between 41 and 49%, while in HFpEF it is greater than 50% [4].

Heart failure with preserved ejection fraction (HFpEF) affects approximately 3 million people in the United States and 13 million worldwide [5].

Studies conducted in sub-Saharan Africa have shown a growing incidence of this condition in the region. For example, a study in Cameroon found that HFpEF accounted for 10% of heart failure cases in a cardiology department in Yaoundé. Furthermore, a comparative study at the Abidjan Heart Institute showed that HFpEF was present in 25% of heart failure patients. These figures indicate that HFpEF is a growing public health problem in sub-Saharan Africa [6][7].

HFpEF is associated with high morbidity and mortality, as well as a poor prognosis [5]. The prognosis of patients with HFpEF is influenced by several factors, including clinical and individual characteristics as well as associated complications [8].

Predictors of mortality related to HFpEF vary worldwide. In Western countries, they are primarily hypertension, overweight, renal insufficiency, atrial fibrillation, tachycardia, loss of atrial systole, and cardiac arrhythmias [9][10]. In sub-Saharan Africa, poor clinical and paraclinical prognostic factors include delayed treatment, severe cardiac involvement, and significant comorbidities [10]. In Côte d’Ivoire, despite its increasing prevalence and significant impact on mortality, predictors of mortality related to HFpEF remain poorly understood.

This study is justified by the need to address the lack of local information on predictive factors of mortality in patients with heart failure with preserved ejection fraction (HFpEF). Understanding the characteristics of patients treated at the Abidjan Cardiology Institute between 2019 and 2023 will allow for better targeting of medical interventions and the improvement of prevention and treatment strategies. By identifying specific risk factors, this study can contribute to reducing mortality and improving patients’ quality of life; hence our main objective: to study predictive factors of mortality in patients with HFpEF.

A better understanding of these predictive factors will allow us to optimize the management of patients with HFpEF in order to reduce mortality.

This was a retrospective cross-sectional analytical study of the records of patients hospitalized for heart failure in the medical department of the Abidjan Cardiology Institute between January 2019 and December 2023, a period of 60 months.

We selected a total of 1137 patient records of individuals hospitalized for heart failure during the study period. Of these, 307 presented with heart failure, with 34 incomplete or unusable records, leaving 273 complete and usable records, resulting in a frequency of 273/1137, or 24%.

The inclusion criteria were as follows. Patients aged 18 years and older with heart failure with preserved ejection fraction (HFpEF), defined according to the 2021 ESC guidelines as the presence of symptoms and/or physical signs of heart failure with a left ventricular ejection fraction (LVEF) ≥ 50% associated with an elevated NT-proBNP level above 220 pg/ml and also structural abnormalities (the presence of left atrial > 34 ml/m² and/or left ventricular hypertrophy (LVH) and functional abnormalities (E/e ≥ 9 ; pulmonary arterial systolic pressure (PAPS)) > 35 mmHg).

Medical records of patients with heart failure and an LVEF < 50% were excluded.

The data were collected using a standardized survey form and univariate and multivariate analysis methods. The following factors were recorded: epidemiological (age, sex), clinical (cardiovascular risk factors, functional and physical signs, etiologies, comorbidities), paraclinical (electrocardiographic, echocardiographic, radiological and biological abnormalities), therapeutic (the fantastic 4), and evolutionary (mortality rate).

Data entry and analysis were performed using Microsoft Word 2016 and Excel 2016. For data analysis, we used SPSS 20 and Microsoft Excel 2016. Qualitative variables are expressed as proportions and quantitative variables are expressed as measures of central tendency and dispersion.

We also used univariate analysis methods to search for a statistically significant link between sociodemographic, clinical, paraclinical, therapeutic, and evolutionary variables and the occurrence of death.

Variables that showed a statistically significant association with the occurrence of death were included in a multivariate regression model to control for confounding factors in order to identify predictors of mortality related to HFpEF. The significance level for the statistical tests was set at 0.05, with odds ratios (OR) calculated and a 95% confidence interval.

In our study, the predictive factors associated with mortality in heart failure with preserved ejection fraction (HFpEF) are: advanced NYHA stages and rhythm disturbances exacerbated by atrial fibrillation (Table 1).

Table 1.Synopsis of sociodemographic, clinical, paraclinical, therapeutic and evolutionary data.

The frequency of heart failure with preserved ejection fraction (HFpEF) was 24%, with a male predominance.

Patients were admitted primarily for NYHA stage IV dyspnea and with global heart failure in most cases (52.38%).

The etiology was dominated by hypertensive heart disease (58.61%), followed by ischemic heart disease (9.52%) (Table 2).

Table 2.Distribution of ICFEP patients according to etiology.

Several comorbidities were observed, primarily diabetes (7.33%), followed by coronary artery disease (6.96%). Treatments were exclusively pharmacological. Furosemide was used in 72.89% of patients, followed by beta-blockers (56.78%) and anticoagulants (50.18%). Complications occurring during hospitalization were dominated by acute renal failure (4.40%), followed by anemia and pneumonia (2.56%), then hyponatremia (2.20%), and finally arrhythmias (2.5%). The majority of patients with heart failure associated with comorbidities had a favorable outcome (Table 3).

Table 3.Logistic regression model for determining mortality risk factors.

We encountered a major difficulty, namely the lack of data in medical records, which could compromise the quality of our results. Furthermore, given the retrospective nature of our study, we only assessed factors associated with in-hospital mortality, and these results cannot be extrapolated to predict mortality in patients who survived hospital discharge, were followed up in outpatient settings, and were subsequently lost to follow-up.

In our study, the prevalence of heart failure with preserved ejection fraction (HFpEF) was approximately 24% among hospitalized patients. This prevalence is close to those previously observed in Côte d’Ivoire (25%) [7] and Senegal (28.8%) [11]. Higher hospital prevalences have been reported in African studies, notably in Nigeria (39.5%) [12], while they were lower in other studies conducted in Cameroon (10%) [6] and Côte d’Ivoire (15%) [13]. On a regional or international scale (Latin America, Middle East, North Africa), this prevalence of HFpEF could reach 65% [14]. This difference in distribution could probably be explained by variations in the sample size of the studied population, the age of the patients, their ethnic origin, and the updated threshold values used to define left ventricular ejection fraction (LVEF) during the study.

Our study revealed a male predominance of HFpEF (59%), unlike the studies by Abebe in Ethiopia and Benjamin in the United States, which observed a female predominance in 76% and 63% of cases, respectively [15][16]. Our results therefore suggest that men are more likely to develop HFpEF. The Framingham study, on the other hand, showed that female sex and atrial fibrillation were associated with a twofold increased risk of developing HFpEF [17].

The mean age of patients with heart failure in our study was 54.89 ± 18.18 years. In Africa, specifically in a study conducted in Togo, this mean age was 52 ± 16.7 years [18], and in a study conducted in Djibouti, it was 55 ± 12 years [19]. However, this mean age was significantly lower than that observed in American and European studies. In the latter, the mean age was 79 ± 7.6 years in the United States [20] and 71 ± 12 years in Europe [21]. This difference could be related to the lower life expectancy in sub-Saharan Africa.

Regarding clinical characteristics, in our study, hypertension was the main cardiovascular risk factor associated with heart failure with preserved ejection fraction (HFpEF), at 61.90%. This frequency was similar to that observed in Bamba-Kamagaté, Côte d’Ivoire (69.7%) [13]. However, it was the most frequent etiology of heart failure in sub-Saharan Africa (45.4% and 85.9%, respectively [7][22]), as well as in the United States (65%) [20] and Europe (59%) [21]. In African Americans, hypertension was present in 96.1% of patients with diastolic dysfunction [23]. Upon admission to the ICA, ICFEP patients were mostly admitted for stage IV (50%) and stage III (40%) dyspnea according to the NYHA classification, as in a Moroccan study where heart failure patients were mostly admitted at stages III and IV (54%) [24].

More than half of our patients with HFpEF presented with global heart failure (52%), followed by left heart failure (39%), as reported by some authors in Africa [25][26]. Global heart failure was the most frequent clinical manifestation; this could be due to late consultation, precarious living conditions, and insufficient or non-existent healthcare resources, which could explain this progression to severe forms [22].

The most common comorbidities were diabetes (7.33%), followed by coronary artery disease. Our results contradict those of other African studies [11][13][27][28]. The prevalence of diabetes in our study was 7.33%, while it was 44% in Nurcan [23], 45% in Mouhamed Cherif [11], and 21% in Shamagian [29].

Renal failure was the most frequent decompensation factor (4.40%), followed by pneumonia and anemia (2.56%). Our results are contrary to those of the THESUS-HF multicenter study, where the most frequently observed decompensation factors were poor treatment adherence, followed by bronchopulmonary infection [30].

The etiologies of HFpEF were dominated by hypertensive heart disease (58.61%). Our results are comparable to those of Traoré (85.6%) [7] and Bamba-Kamagaté (65.7%) [13] in Côte d’Ivoire. This could be related to the high prevalence of hypertension in our setting and its pathophysiological consequences, notably the development of left ventricular hypertrophy with increased arterial stiffness [31]. Ischemic heart disease was the second most frequent cause of HFpEF in our study (9.52%). This result is comparable to that of a Chinese study (29.3%) [32] and an American study (21%) [20]. Ischemic heart disease has also been found to be the second leading cause of HFpEF, although in a smaller proportion (4.6%) [7]. This higher proportion observed in our study could be explained by the increasing activity of interventional cardiology over the years at the ICA, allowing for more accurate diagnosis.

In paraclinical studies, radiological features were consistent with cardiomegaly in most of our patients (90%). These data do not agree with those of Bamba-Kamagate [13], where cardiomegaly was rare (23.6%) in HFpEF. This difference could probably be attributed to variations in the sample size of the studied population.

In our study, the electrocardiogram (ECG) revealed that patients with HFpEF presented, in decreasing order of frequency, with atrial fibrillation (AF) in 45.42% of cases, followed by left ventricular hypertrophy (LVH) in 28.94% of cases. In the literature, the prevalence of atrial fibrillation (or AF) in HFpEF was similar, at 20%, 30%, and 40%, respectively [10][33][34], while left ventricular hypertrophy (LVH) was described as the most frequent echocardiographic morphological abnormality [35].

Two-dimensional echocardiography was the paraclinical examination of choice to confirm the presence of heart failure with preserved ejection fraction (HFpEF). In our series, echocardiography revealed a preserved left ventricular ejection fraction (LVEF), with a mean of 58.3 ± 7.10%. The mean left ventricular end-diastolic diameter (LVEDD) was 48.15 ± 9.08 mm, which is consistent with data from the literature showing that, in HFpEF, left ventricular size remains normal for a prolonged period in the absence of associated factors, such as myocardial ischemia [26]. Left atrial dilation was uncommon in our series, observed in 0.73% of patients. These figures are significantly lower than those reported by Mboup [11], which were 75%. In general, the severity of dilation was correlated with the severity of diastolic dysfunction [17].

In biology, the level of NT-proBNP was high, with an average of 6077.9 + 833 pg/ml, which was also correlated with ICFEP [18].

Regarding therapeutic characteristics, unlike the treatment of heart failure with reduced ejection fraction (HFrEF), the treatment of heart failure with preserved ejection fraction (HFpEF) has remained largely empirical in clinical practice. Its main objective was to reduce signs of congestion and improve symptoms and quality of life [19]. Thus, the 2022 European Society of Cardiology guidelines for HFpEF remained well-structured and informative. Furosemide and beta-blockers were the standard treatment for heart failure; their use rates were 79.89% and 56.78%, respectively, in our series. In Hong Kong SAR, YI showed that only diuretic therapy (furosemide, thiazide) significantly improved symptoms and quality of life, while irbesartan or ramipril provided little benefit [32]. Dapagliflozin or empagliflozin reduced the combined risk of worsening heart failure and cardiovascular death in patients with preserved left ventricular ejection fraction, while also demonstrating a good safety profile [19]. They currently represent the only therapeutic class whose efficacy has been demonstrated [13].

In our series, only 2.2% of patients benefited from glifozine; this could be explained by the fact that our study began well before these recommendations.

In evolutionary characteristics, in our series, the average length of hospital stay was 6 days, similar to that observed by Goyal in the United States (more than 4 days) [14]. The one-year mortality rate was 9% in our study. Abebe, in Ethiopia, reported different figures, with a one-year mortality rate of 14.02% at the ICFEP [15]; however, this rate was higher in Canada (22.2%) and the United States (29%) [5]. This difference is likely due to variations in the size and characteristics of the study population sample. It is possible that the mortality rate was underestimated in our case because we did not account for deaths occurring before or after hospitalization, nor for those of patients lost to follow-up.

This study carried out at the Abidjan Cardiology Institute showed that ICFEP is an increasingly common entity in our context.

ICFEP occurred in elderly male subjects admitted at NYHA stage IV with global heart failure.

The comorbidities were primarily diabetes, coronary artery disease, renal failure, and atrial fibrillation.

The dominant etiology was arterial hypertension (HTA).

This is the ideal place to remind and raise public awareness about early screening and effective management of cardiovascular risk factors.